Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Reuters NewMedia, Inc. - Thursday December 19 11:56 AM EST
"We are pleased that Ontario's formulary has taken the action necessary to ensure that Zerit is available to all persons with AIDS and we hope that all (Canadian) provinces will follow in the near future," said Sophia Fourie, vice president, Scientific Affairs, Bristol-Myers Squibb Pharmaceutical Group, in a statement.
Zerit, or stavudine, also known as d4T, is an antiretroviral agent active against the human immunodeficiency virus (HIV). Zerit belongs to a class of antiretroviral drugs called necleoside analogues.
It was discovered, developed and is manufactured by Bristol-Myers Squibb. Zerit, which was cleared by Canada's Health Protection Board in March 1996 and has been available for commercial sale in Canada since July 1996, is indicated for the treatment of adults with HIV infection who have undergone prior treatment with Glaxo Wellcome GLXO.L Plc's zidovudine (AZT), Bristol-Meyers said.
Bristol-Meyers said the Ontario drug plan's inclusion of Zerit was an important step for Canada-wide provincial government drug plan coverage because 42 percent of reaported Canadian AIDS patients reside in Ontario.
((Reuters Montreal bureau 514-985-2434))
961219
RE961292
Copyright © 1996 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .